PTPIOTCPharmaceutical PreparationsFiscal year ends December 31
Petros Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.00+0.00 (+5.56%)
Close on Oct 19, 2026
- Market cap
- $135.07K
- P/E (TTM)
- –
- Dividend yield
- –
Petros Pharmaceuticals, Inc. revenue by segment
By business segment
| Revenue | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|
| Medical Devices | $3.15M | $3.54M | $3.26M | $3.21M | $3.20M | 61.6% | -10.9% |
| Prescription Medications | $1.96M | $2.29M | $2.73M | $4.61M | $6.36M | 38.4% | -14.2% |
By product or service
By region
| Revenue | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|
| United States | $4.04M | $4.53M | $4.80M | $6.57M | $8.56M | 79.1% | -10.7% |
| International | $1.07M | $1.30M | $1.19M | $1.24M | $1.00M | 20.9% | -17.5% |
From the segment and revenue-disaggregation notes of Petros Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.